Is RNAC or RPRX more undervalued in 2026?

CirclFi compares Cartesian Therapeutics, Inc. (RNAC) and Royalty Pharma plc (RPRX) using 13 institutional-grade valuation models. RNAC has a Quality of Company score of 4.4/10 while RPRX scores 8.4/10.

Which is a better buy — RNAC or RPRX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do RNAC and RPRX valuations compare?

RNAC at $7.21 and RPRX at $54.48 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

RNAC vs RPRX Valuation Comparison 2026 — Intrinsic Value Analysis

RNAC

Biotechnology

Cartesian Therapeutics, Inc.

Quality

4.4

out of 10

Value Trap

LOW

Price

$7.21

Last close

Models

7/13

Active

RPRX

Biotechnology

Royalty Pharma plc

Quality

8.4

out of 10

Value Trap

SAFE

Price

$54.48

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	RNAC Fair Value	RNAC Upside	RPRX Fair Value	RPRX Upside
Bayesian DCF	Intrinsic	$5.09	-28.0%	$57.58	+5.7%
Earnings Power Value	Intrinsic	—	—	$1.77	-96.8%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$10.81	+49.9%	$49.54	-9.1%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for RNAC vs RPRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RNAC vs RPRX — Which Stock Is More Undervalued?

RPRX scores higher with a 8.4/10 quality rating vs RNAC's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Cartesian Therapeutics, Inc. (RNAC) and Royalty Pharma plc (RPRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RNAC currently trades at $7.21 with a QOC of 4.4/10, while RPRX trades at $54.48 with a QOC of 8.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).